Hormone replacement therapy and lipid–lipoprotein concentrations

• Published in: European journal of obstetrics & gynecology and reproductive biology Vol. 85; no. 1; pp. 31 - 41
• Main Authors: Gökmen, Oya, Yapar Eyi, Elif G
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01.07.1999; Elsevier
• Subjects: Adult; Biological and medical sciences; Cholesterol - blood; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Cholesterol, VLDL - blood; Dydrogesterone - administration & dosage; Dydrogesterone - adverse effects; Dydrogesterone - therapeutic use; Estrogen; Estrogen Replacement Therapy; Estrogens, Conjugated (USP) - administration & dosage; Estrogens, Conjugated (USP) - adverse effects; Estrogens, Conjugated (USP) - therapeutic use; Female; Genital system. Reproduction; Hormone replacement therapy; Humans; Lipid-lipoprotein levels; Lipids - blood; Lipoproteins - blood; Longitudinal Studies; Medical sciences; Medroxyprogesterone Acetate - administration & dosage; Medroxyprogesterone Acetate - adverse effects; Medroxyprogesterone Acetate - therapeutic use; Menopause, Premature; Middle Aged; Ovariectomy; Pharmacology. Drug treatments; Postmenopause; Progesterone; Progesterone Congeners - administration & dosage; Progesterone Congeners - adverse effects; Progesterone Congeners - therapeutic use; Prospective Studies; Triglycerides - blood; Tropical medicine; Asia; Turkey; Hormone replacement therapy; Progesterone; Lipid-lipoprotein levels; Estrogen; Human; Replacement therapy; Estroprogestagen; Cholesterol HDL; Cholesterolemia; Treatment efficiency; Menopause; Adult; Female; Comparative study; Triglyceridemia
• ISSN: 0301-2115; 1872-7654
• DOI: 10.1016/S0301-2115(98)00279-6

Objective: To evaluate the links between hormone replacement therapy and lipid-lipoprotein concentrations (total cholesterol [T.Ch] triglycerids, high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C] and very low density lipoprotein cholesterol [VLDL-C]) in a total of 6416 postmenopausal women. Study design: Open prospective longitudinal study. Of the 2184 surgical postmenopausal women, 1102 received conjugated equine estrogen (CEE), and 1082 transdermal estradiol (TDE 2). Of the 4232 natural postmenopausal women: 1073 received CEE+medroxyprogesterone acetate (MPA), 1068 CEE+dydrogesterone (DD), 1044 TDE 2+MPA, 1047 TDE 2+DD. Lipid-lipoprotein concentrations were evaluated by using a SPSS program at 1,2,3,4,5,6,7 years of therapy and cumulatively. Results: Cumulative evaluation of the data on estrogen only replacement therapy revealed a significant decrease in T.Ch, LDL-C and VLDL-C, and an increase in HDL-C; however, the increase in HDL-C and triglycerids was significantly higher in CEE than TDE 2 ( P<0.01). Cumulative evaluation of the data on estrogen progestin hormone replacement therapy revealed a significant decrease in T.Ch, LDL-C and an increase in HDL-C for all; however, triglycerides and VLDL levels decreased in TDE 2+MPA and TDE 2+DD groups ( P<0.05). Conclusion: Both the natural and surgical menopause patients were found to have more favorable lipid profiles after treatment with estrogen progesterone combined formulations and estrogen only replacement.